147 related articles for article (PubMed ID: 23014669)
1. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Rohatagi S; Mendell J; Kastrissios H; Green M; Shi M; Patel I; Salazar DE
Thromb Haemost; 2012 Nov; 108(5):887-95. PubMed ID: 23014669
[TBL] [Abstract][Full Text] [Related]
2. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
[TBL] [Abstract][Full Text] [Related]
7. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
9. Establishing Edoxaban's Role in Anticoagulation.
Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban for the prevention of thromboembolic events after surgery.
Gras J
Drugs Today (Barc); 2011 Oct; 47(10):753-61. PubMed ID: 22076490
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
[TBL] [Abstract][Full Text] [Related]
12. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
13. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
14. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
15. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Okuyama H; Hirotomi K; Shinohara K; Saito T
Orthop Traumatol Surg Res; 2017 Dec; 103(8):1193-1196. PubMed ID: 28928048
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Hotta T; Tsubata Y; Hamai K; Tanino A; Kobayashi M; Nakamura A; Sugisaka J; Hongoh M; Ishihara N; Ishikawa N; Yamasaki M; Fujitaka K; Kubota T; Nishimura N; Isobe T
Respir Investig; 2021 May; 59(3):327-334. PubMed ID: 33386292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
